Cargando…
Host-Based Treatments for Severe COVID-19
COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understand...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136924/ https://www.ncbi.nlm.nih.gov/pubmed/37185727 http://dx.doi.org/10.3390/cimb45040203 |
_version_ | 1785032336171073536 |
---|---|
author | Mondini, Lucrezia Salton, Francesco Trotta, Liliana Bozzi, Chiara Pozzan, Riccardo Barbieri, Mariangela Tavano, Stefano Lerda, Selene Hughes, Michael Confalonieri, Marco Confalonieri, Paola Ruaro, Barbara |
author_facet | Mondini, Lucrezia Salton, Francesco Trotta, Liliana Bozzi, Chiara Pozzan, Riccardo Barbieri, Mariangela Tavano, Stefano Lerda, Selene Hughes, Michael Confalonieri, Marco Confalonieri, Paola Ruaro, Barbara |
author_sort | Mondini, Lucrezia |
collection | PubMed |
description | COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understanding of this disease has allowed researchers and clinicians to implement different therapeutic alternatives, depending on both the severity of clinical involvement and the causative molecular mechanism that has been progressively explored. In this review, we analysed the main therapeutic options available to date based on modulating the host inflammatory response to SARS-CoV-2 infection in patients with severe and critical illness. Although current guidelines are moving toward a personalised treatment approach titrated on the timing of presentation, disease severity, and laboratory parameters, future research is needed to identify additional biomarkers that can anticipate the disease course and guide targeted interventions on an individual basis. |
format | Online Article Text |
id | pubmed-10136924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101369242023-04-28 Host-Based Treatments for Severe COVID-19 Mondini, Lucrezia Salton, Francesco Trotta, Liliana Bozzi, Chiara Pozzan, Riccardo Barbieri, Mariangela Tavano, Stefano Lerda, Selene Hughes, Michael Confalonieri, Marco Confalonieri, Paola Ruaro, Barbara Curr Issues Mol Biol Review COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understanding of this disease has allowed researchers and clinicians to implement different therapeutic alternatives, depending on both the severity of clinical involvement and the causative molecular mechanism that has been progressively explored. In this review, we analysed the main therapeutic options available to date based on modulating the host inflammatory response to SARS-CoV-2 infection in patients with severe and critical illness. Although current guidelines are moving toward a personalised treatment approach titrated on the timing of presentation, disease severity, and laboratory parameters, future research is needed to identify additional biomarkers that can anticipate the disease course and guide targeted interventions on an individual basis. MDPI 2023-04-05 /pmc/articles/PMC10136924/ /pubmed/37185727 http://dx.doi.org/10.3390/cimb45040203 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mondini, Lucrezia Salton, Francesco Trotta, Liliana Bozzi, Chiara Pozzan, Riccardo Barbieri, Mariangela Tavano, Stefano Lerda, Selene Hughes, Michael Confalonieri, Marco Confalonieri, Paola Ruaro, Barbara Host-Based Treatments for Severe COVID-19 |
title | Host-Based Treatments for Severe COVID-19 |
title_full | Host-Based Treatments for Severe COVID-19 |
title_fullStr | Host-Based Treatments for Severe COVID-19 |
title_full_unstemmed | Host-Based Treatments for Severe COVID-19 |
title_short | Host-Based Treatments for Severe COVID-19 |
title_sort | host-based treatments for severe covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136924/ https://www.ncbi.nlm.nih.gov/pubmed/37185727 http://dx.doi.org/10.3390/cimb45040203 |
work_keys_str_mv | AT mondinilucrezia hostbasedtreatmentsforseverecovid19 AT saltonfrancesco hostbasedtreatmentsforseverecovid19 AT trottaliliana hostbasedtreatmentsforseverecovid19 AT bozzichiara hostbasedtreatmentsforseverecovid19 AT pozzanriccardo hostbasedtreatmentsforseverecovid19 AT barbierimariangela hostbasedtreatmentsforseverecovid19 AT tavanostefano hostbasedtreatmentsforseverecovid19 AT lerdaselene hostbasedtreatmentsforseverecovid19 AT hughesmichael hostbasedtreatmentsforseverecovid19 AT confalonierimarco hostbasedtreatmentsforseverecovid19 AT confalonieripaola hostbasedtreatmentsforseverecovid19 AT ruarobarbara hostbasedtreatmentsforseverecovid19 |